Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, docetaxel, and zoledronic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective when given together with zoledronic acid in treating patients with breast cancer.

PURPOSE: This randomized phase III trial is studying giving doxorubicin hydrochloride together with cyclophosphamide and docetaxel to see how well it works with or without zoledronic acid in treating patients with large resectable or locally advanced breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer

NCT00525759

Breast Cancer

COMPLETED PHASE2

Combination Chemotherapy in Treating Women With Breast Cancer

NCT00003519

Breast Cancer

COMPLETED PHASE3

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

NCT00793377

Primary Breast Cancer

COMPLETED PHASE3

Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer

NCT01229605

Breast Cancer

WITHDRAWN PHASE2

Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer

NCT00003352

Breast Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* To determine the value of neoadjuvant chemotherapy comprising doxorubicin hydrochloride, cyclophosphamide, and docetaxel with or without zoledronic acid in patients with HER2-negative large resectable or locally advanced breast cancer.

Secondary

* To correlate clinical response with pathological responses in both treatment arms.
* To evaluate the disease-free survival and overall survival of patients treated with this regimen.
* To evaluate the safety and tolerability of adding zoledronic acid to neoadjuvant chemotherapy.
* To evaluate heterogeneity of the ER/PR and HER2 measurement in core biopsy and the surgical specimen.

OUTLINE: Patients are randomized between 2 treatment arms.

* Arm I: Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV on day 1. Patients also receive zoledronic acid IV over 15 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
* Arm II: Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV as in arm I. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAC + Zoledronic acid

six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC) and zoledronic acid (Zometa)

Group Type EXPERIMENTAL

cyclophosphamide

Intervention Type DRUG

docetaxel

Intervention Type DRUG

doxorubicin hydrochloride

Intervention Type DRUG

zoledronic acid

Intervention Type DRUG

neoadjuvant therapy

Intervention Type PROCEDURE

TAC

six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC)

Group Type ACTIVE_COMPARATOR

cyclophosphamide

Intervention Type DRUG

docetaxel

Intervention Type DRUG

doxorubicin hydrochloride

Intervention Type DRUG

neoadjuvant therapy

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cyclophosphamide

Intervention Type DRUG

docetaxel

Intervention Type DRUG

doxorubicin hydrochloride

Intervention Type DRUG

zoledronic acid

Intervention Type DRUG

neoadjuvant therapy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed breast cancer

* Large resectable or locally advanced disease

* T2 (≥ 2 cm and positive lymph nodes), T2 (≥ 3 cm), ≥ T3, T4, any N, M0 disease
* Measurable disease (breast and/or lymph nodes)
* HER2-negative disease by core biopsy
* No evidence of distant metastases (M1)
* No prior breast cancer

PATIENT CHARACTERISTICS:

* Female
* Menopausal status unspecified
* WHO performance status 0-2
* Not pregnant or nursing
* WBC ≥ 3.0 x 10\^9/L
* Neutrophil count ≥ 1.5 x 10\^9/L
* Platelet count ≥ 100 x 10\^9/L
* Bilirubin ≤ 1.5 times upper limit of normal (UNL)
* ALT and/or AST ≤ 2.5 times UNL
* Alkaline phosphatase ≤ 5 times UNL
* Creatinine clearance ≥ 50 mL/min
* Accessible for treatment and follow-up
* No previous malignancy within the past 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
* No peripheral neuropathy \> grade 2 (of any cause)
* No other serious diseases including recent myocardial infarction, clinical signs of cardiac failure, or clinically significant arrhythmias
* No poor dental health
* No known hypersensitivity reaction to any of the components of the treatment
* No medical or psychological condition that, in the opinion of the investigator, would not permit the patient to complete the study or sign meaningful informed consent

PRIOR CONCURRENT THERAPY:

* No prior breast surgery except for biopsy
* No prior chemotherapy or radiotherapy
* No prior bisphosphonates

Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No